Johannes Sperzel

Dr. Johannes Sperzel


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2006 in Clinical Research in Cardiology
Verified
Journal Article
Closed access
PDF file
WJWerner Jung
Werner Jung
DADietrich Andresen
Dietrich Andresen
MBMichael Block
Michael Block
DBDirk Böcker
Dirk Böcker
SHStefan H. Hohnloser
Stefan H. Hohnloser
JSJohannes Sperzel
Johannes Sperzel

29 May 2015 in EP Europace
Verified
Journal Article
Open access
PDF file
JSJohannes Sperzel
Johannes Sperzel
HBHaran Burri
Haran Burri
DGDaniel Gras
Daniel Gras
FTFleur V.Y. Tjong
Fleur V.Y. Tjong
RKReinoud E. Knops
Reinoud E. Knops
PDPascal Defaye
Pascal Defaye
Despite undisputable benefits, conventional pacemaker therapy is associated with specific complications related to the subcutaneous device and the transvenous leads. Recently, two miniaturized leadless pacemakers, Nanostim™ (St. Jude Medical) and Micra™ (Medtronic), which can be completely implanted inside the right ventricle using steerable delivery systems, entered clinical application. The WiCS™-cardiac resynchronisation therapy (CRT) system (wireless cardiac stimulation for CRT, EBR Systems) delivers leadless left ventricular endocardial stimulation for cardiac resynchronization. In addition to obvious cosmetic benefits, leadless pacing systems may have the potential to overcome some complications of conventional pacing. However, acute and long-term complications still remains to be determined, as well as the feasibility of device explantation years after device placement.

11 October 2011 in EP Europace
Verified
Journal Article
Open access
PDF file
JSJohannes Sperzel
Johannes Sperzel
WDWilfried Dänschel
Wilfried Dänschel
KGKlaus-Jürgen Gutleben
Klaus-Jürgen Gutleben
WKWolfgang Kranig
Wolfgang Kranig
PMPeter Mortensen
Peter Mortensen
CRChristopher A. Rinaldi
Christopher A. Rinaldi
Cardiac resynchronization therapy (CRT) is sometimes complicated by elevated pacing thresholds and phrenic nerve stimulation (PNS), both of which may require that the coronary sinus lead be repositioned. The purpose of this study was to evaluate the performance of a novel quadripolar electrode lead and cardiac resynchronization therapy-defibrillator (CRT-D) device that enables electrical repositioning, potentially obviating a lead reposition procedure. Patients indicated for CRT were enrolled and received a quadripolar electrode lead and CRT-D device (Quartet®model 1458Q and Promote Q®; St Jude Medical, Sylmar, CA, USA). Electrical data, and the presence of PNS during pacing from each left ventricular (LV) configuration, were documented at pre-hospital discharge and at 1 month. Seventy-five patients were enrolled and 71 were successfully implanted with a Quartet®lead. Electrical measurements were stable over the follow-up period. Ninety-seven per cent (64 of 66) of patients had one or more programmable configurations with a threshold <2.5 V and no PNS vs. 86% (57 of 66) if only conventional bipolar configurations were considered. Physicians were able to use the increased programming options to manage threshold changes and PNS. The new quadripolar electrode LV lead provides more programming options to address common problems faced when managing CRT patients. Electrical measurements from new vectors are comparable with conventional configurations. Furthermore, 11% of patients in the study suffered PNS on all conventional bipolar vectors.

6 July 2012 in European Heart Journal
Verified
Journal Article
Open access
PDF file
DEDamir Erkapic
Damir Erkapic
JSJohannes Sperzel
Johannes Sperzel
SSSascha Stiller
Sascha Stiller
UMUlf Meltendorf
Ulf Meltendorf
JMJohann Mermi
Johann Mermi
FIfor the INSURE Investigators
for the INSURE Investigators
Prevention of sudden cardiac death by means of the implantable cardioverter/defibrillator (ICD) is considered to be a lifelong therapy. However, it is still unresolved if patients who never experienced an appropriate ICD intervention during generator longevity really need to undergo device replacement. The INSURE trial was a multicentre prospective observational cohort study that enrolled patients at the time of their first ICD replacement. Patients with and without previous appropriate ICD therapy were enrolled prospectively and were evaluated every 3–6 months after ICD replacement. Primary endpoint of the study was the first occurrence of appropriate ICD therapy after device replacement. Five hundred and ten patients (83% males, mean age 65 ± 10 years, mean ejection fraction 39 ± 16%) were enrolled between 2002 and 2007 in the study after an average lifespan of their first ICD generator of 62 ± 18 months. Three years after elective ICD replacement, the rates of appropriate ICD therapies in patients with (n = 245) and without (n = 265) former appropriate ICD intervention were 48.1 and 21.4% (adjusted hazard ratio 3.08, CI: 2.15–4.39, P < 0.001). Notably, no predictive factors for lower need of ICD therapy could be identified in patients without prior appropriate ICD intervention. In this study, a significant number of ICD-indicated patients without the need for therapy by their first device received appropriate ICD intervention after generator replacement. There were no predictors for lower need of ICD therapy. Hence, ICD replacement appears still necessary in patients without prior ICD interventions.

19 January 2018 in EP Europace
Verified
Journal Article
Closed access
PDF file
JSJohannes Sperzel
Johannes Sperzel
PDPascal Defaye
Pascal Defaye
PDPeter-Paul Delnoy
Peter-Paul Delnoy
JGJuan Jose Garcia Guerrero
Juan Jose Garcia Guerrero
RKReinoud E Knops
Reinoud E Knops
PNPetr Neuzil
Petr Neuzil
A prospective, single-arm, multicentre, post-market study was conducted to confirm the short-term safety of the Nanostim™ leadless pacemaker (LP). In this study, we report the primary results of the LEADLESS Observational Study. Subjects meeting VVIR pacemaker indications were enrolled and followed up after successful LP implantation, prior to discharge and post-implantation at 90 days, 180 days, and every 6 months thereafter for the assessment of adverse events. The primary safety endpoint was evaluated in terms of freedom from serious adverse device effects (SADEs) at 6 months in 300 subjects. Data for all enrolled subjects were also presented. A total of 470 subjects were enrolled (75.8 ± 13.1 years, 62.8% male). The study paused in April 2014 following the occurrence of perforation events that led to changes in the protocol and investigator training. Freedom from SADEs, evaluated in 300 subjects enrolled post-pause, was 94.6% (95% confidence interval 91.0–97.2%) and demonstrated non-inferiority to a performance goal of 86% (P < 0.0001). Eighteen SADEs were observed in 16 (5.3%) subjects. The most frequently occurring events were cardiac perforation (1.3%), device dislodgement (0.3%), and vascular complications (1.3%). In the 470 subjects, 34 similar SADEs were observed in 31 (6.6%) subjects. After stratifying the results in relation to the study pause, there was a statistically significant difference in the final LP location (septum vs. apex) (P < 0.0001) and the number of repositioning attempts (<2 vs. ≥2) (P = 0.05) and a decreasing trend in the rates of cardiac perforation and device dislodgement. The primary safety endpoint at 6 months was successfully met for the Nanostim LP. The occurrence of cardiac perforation and device dislodgement declined after changes following the study pause.

1 November 2005 in Heart Rhythm
Verified
Journal Article
Closed access
JSJohannes Sperzel
Johannes Sperzel
GMGoran Milasinovic
Goran Milasinovic
TSTimothy W. Smith
Timothy W. Smith
HMHardwin Mead
Hardwin Mead
JBJohan Brandt
Johan Brandt
SCSteven Compton
Steven Compton